Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)
Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Royalty Pharma's pe ratio was 39.8× on Nov 11, 2026, against 24.6× a year earlier. Over the last 5 years it ranged from 10.9× to 360.3×, with a median of 28.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 39.8× | +16.1 |
| 2025 | Dec 31, 2025 | 23.7× | +12.5 |
| 2024 | Dec 31, 2024 | 11.2× | −60.8 |
| 2023 | Dec 29, 2023 | 72.0× | +38.0 |
| 2022 | Dec 30, 2022 | 34.1× | +13.4 |
| 2021 | Dec 31, 2021 | 20.6× | – |
See a number that looks wrong?